Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (MBRX)
NASDAQ:MBRX
MBRX Stock Chart & Stats
$0.48
-$0.01(-0.56%)
At close: 4:00 PM EST
$0.48
-$0.01(-0.56%)
Day’s Range― - ―
52-Week Range$0.25 - $3.65
Previous CloseN/A
Volume63.82K
Average Volume (3M)2.74M
Market Cap
$23.90M
Enterprise Value-$2.45M
Total Cash (Recent Filing)$7.56M
Total Debt (Recent Filing)$292.00K
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Nov 17, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding49,498,577
10 Day Avg. Volume1,958,319
30 Day Avg. Volume2,738,732
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.10
Enterprise Value/Revenue-19.44
Enterprise Value/Gross Profit87.48
Enterprise Value/Ebitda0.09
Forecast
1Y Price Target
$6.67Price Target Upside1289.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPhase 3 MIRACLE study recruitment picks up momentum, highlighting the unmet need in relapsed or refractory acute myeloid leukemia (r/r AML).
Drug DevelopmentAnnamycin’s differentiated non-cardiotoxic profile could position it as the first anthracycline viable for chronic or maintenance use in pancreatic cancer.
Market PotentialThe case for Annamycin keeps getting stronger with the expansion of potential opportunity into pancreatic cancer.
Bears Say
Stock PerformanceMBRX shares traded down following announcement of a warrant inducement transaction that brought in $6M in gross proceeds.
Moleculin Biotech News
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $0.25 and its highest was $3.65 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $23.90M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Nov 17, 2025 which is in 19 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Aug 13, 2025. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.43 by -$0.06.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -0.26.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 49,498,577 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.43. Following the earnings report the stock price went up 1.515%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
Company Description
Moleculin Biotech
Moleculin Biotech, Inc. (MBRX) is a clinical-stage pharmaceutical company focused on the development of oncology drug candidates. The company operates primarily in the biotechnology sector, specializing in the research and development of novel anti-cancer agents. Moleculin's core products include a portfolio of small-molecule drug candidates targeting highly resistant tumors and hard-to-treat cancers. The company's lead compounds are designed to disrupt cancer cell metabolism and enhance the body's immune response against tumors.
MBRX Stock 12 Month Forecast
Average Price Target
$6.67
▲(1289.58% Upside)
Technical Analysis
Ownership Overview
2.13% Insiders
0.13% Mutual Funds
0.22% Other Institutional Investors
97.34% Public Companies and Individual Investors
Options Prices
Currently, No data available
---